Objective:

To evaluate patient satisfaction with HETs in relapsing-remitting MS, focusing on the impact of administration on quality of life and treatment burden, and to identify factors influencing preferences for personalized treatment strategies.

Key Findings:

• Self-administration of subcutaneous ofatumumab at home resulted in more favorable patient-reported outcomes regarding temporal and organizational burden, perceived therapeutic impact, and administration experience compared to other high-efficacy therapies.
• Less than 25% of patients were offered home self-administration of high-efficacy therapy, indicating gaps in shared decision-making and the need for improved communication between patients and healthcare providers.

Interpretation:

The findings suggest that home-based self-administration of ofatumumab may enhance patient satisfaction and engagement compared to other high-efficacy treatments, emphasizing the importance of patient autonomy in treatment choices and its implications for clinical practice.

Limitations:

• The study used a convenience sample, which may limit the generalizability of the findings and introduce selection bias.
• Comparisons were not made between individual drugs, focusing instead on broader categories, which may overlook specific treatment nuances.

Conclusion:

The study highlights the need for more personalized treatment strategies that consider patient preferences and experiences, particularly regarding the administration of therapies, to improve overall patient care.